Biomerieux (EYWN)

Sell your shares and run for the hills, it will be a great riddance,

Go easy on the bottle.... calm down

Go easy on the bottle.... calm down

Good stuff CarlinNM, really good...!

These sensors work by splitting a laser beam, sending it around a tiny microscopic optical coil loop, and measuring the phase shift of the light as the vehicle moves or rotates. To make these sensors incredibly accurate, you need two things that ha

thanks, but that wasn't a draft of anything going on X ... all the media talk around the government taking equity stakes in AI is giving me plenty of opportunity to vent

$ILLR_ so why are you guys trying to spin what I’m saying when I said clowns I meant the group of idiots before this CEO came in you guys don’t even realize what is about to happen. OK can’t you read between the lines? Aren’t you following Twitter look under the Spurs it’s out it’s everywhere. The

“.30’s” has the 14 share buyback been completed? Tia

The New Big is Small BS. First in a series of, as in turned out one, such educational videos - just another initiative that wen't nowhere.

That is what data from large, well-designed and executed phase 3 trials will finally answer. We’ll likely know one way or the other by sometime in 2030. That, of course, assumes Anavex will still around.

NEW UPDATE ON VUME 1.3.34. Njew versions every day! Looking better and betterr and more complete

NVDA! a interest rate fear hits big tech stocks
https://investorshub.advfn.com/uimage/uploads/2026/6/6/wfbnbIMG_2174.png

Wertheim & CO delivers high-quality advisory solutions tailored to premier privately held middle-market businesses and private investment firms.


Discreet and confidential transactions handled through private negotiations.



Full-spectrum M&A ad

🙏🙏🙏

WHAT'S YOUR SOURCE

Five year subchapter 5 plan for Nutranomics INC. - 2026 is our year.

https://www.troutman.com/wp-content/uploads/2025/03/tp_creditors-rights-toolkit_subchaptervbankruptcy.pdf

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®June 6, 2026 4:45 PM
Business Wire New data from CATALYST and MOMENTUM trials presented

Nasrat would not have delayed if he was not sure we can do it and get paragraph 4 first to file.

He delivers.

Here ya go...

Memorandum:

https://drive.google.com/file/d/1ur0tbW0KGZv4LJm4p2GHG5uJGQQqOnTN/view

Declaration:

https://drive.google.com/file/d/1LoHKsClX1RIQn3ymAbx_qr1mNUwMVPSc/view

I haven't read them yet. Up North, gota run

This one has been a total POS. I finally dumped it awhile ago before that 1 for 2500 reverse split. Of course they will dilute again. Will never be anything and was just a stinky OTC trip pinky that burned all previous shareholders.

I'd be stunned if there were an acquisition announcement this year and I certainly don't oppose a buyout at some point in the distant future. Part of my concern is my cost basis and selling price, as I'm not one of the fortunate investors who owns this at a sub-$1 value. If an acquisition happens

“ABT is now beset by (spurious, IMO) litigation on multiple fronts in its nutrition business”
Gives me pause too but a pretty close to worst case scenario may be priced in already but I can’t really be sure. Bayer is the poster child for the worst case scenario and they may be getting good ne

If you don't think MMs manipulate OTC prices I can see why you think Nexboard is real. That's why they are called Market MAKERS. Do you think this run of 350% wasn't due to the note holders and the MM manipulating the price. Just like any of the groups that follow their leader they run the volume an

My3sons,, it's not the first time they're posting negative articles. As you said, it's more a matter of pattern of analysis that biased the result.